Results for tag: "Gastric Inhibitory Polypeptide Receptor"

The Gastric Inhibitory Polypeptide Receptor (GIPR) is a G-protein coupled receptor that is involved in the regulation of glucose metabolism and appetite. It is a target for the development of drugs for the treatment of gastrointestinal diseases such as obesity, diabetes, and metabolic syndrome. GIPR agonists are being developed to reduce food intake and improve glucose metabolism, while GIPR antagonists are being developed to reduce appetite and improve glucose tolerance. GIPR drugs are being developed by a number of pharmaceutical companies, including Novo Nordisk, Eli Lilly, Merck, and AstraZeneca. These companies are focusing on the development of GIPR agonists and antagonists for the treatment of obesity, diabetes, and metabolic syndrome. Additionally, there are several biotechnology companies that are developing GIPR-targeted therapies, such as Orexigen Therapeutics, Arena Pharmaceuticals, and Zafgen. Show Less Read more